Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

170 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Eriksson BI, et al. Thromb Haemost. 1997 Nov;78(5):1404-7. Thromb Haemost. 1997. PMID: 9408027
New therapeutic options in deep vein thrombosis prophylaxis.
Eriksson BI. Eriksson BI. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9. doi: 10.1016/s0037-1963(00)90093-3. Semin Hematol. 2000. PMID: 11055889 Review.
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR; RE-MODEL Study Group. Eriksson BI, et al. J Thromb Haemost. 2007 Nov;5(11):2178-85. doi: 10.1111/j.1538-7836.2007.02748.x. J Thromb Haemost. 2007. PMID: 17764540 Clinical Trial.
Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment.
Kälebo P, Ekman S, Lindbratt S, Eriksson BI, Pauli U, Zachrisson BE, Close P. Kälebo P, et al. Among authors: eriksson bi. Thromb Haemost. 1996 Dec;76(6):893-6. Thromb Haemost. 1996. PMID: 8972007
A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. Eriksson BI, et al. Thromb Haemost. 1995 Mar;73(3):398-401. Thromb Haemost. 1995. PMID: 7667822 Clinical Trial.
Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P. Eriksson BI, et al. Thromb Haemost. 1994 Aug;72(2):227-31. Thromb Haemost. 1994. PMID: 7831657 Clinical Trial.
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators. Eriksson BI, et al. J Thromb Haemost. 2006 Jan;4(1):121-8. doi: 10.1111/j.1538-7836.2005.01657.x. J Thromb Haemost. 2006. PMID: 16409461 Clinical Trial.
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; ONYX-2 STUDY GROUP. Eriksson BI, et al. J Thromb Haemost. 2010 Apr;8(4):714-21. doi: 10.1111/j.1538-7836.2010.03748.x. Epub 2010 Jan 17. J Thromb Haemost. 2010. PMID: 20088935 Clinical Trial.
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study.
Eriksson BI, Dahl OE, Lassen MR, Ward DP, Rothlein R, Davis G, Turpie AG; Fixit Study Group. Eriksson BI, et al. J Thromb Haemost. 2008 Mar;6(3):457-63. doi: 10.1111/j.1538-7836.2007.02872.x. Epub 2007 Dec 12. J Thromb Haemost. 2008. PMID: 18088349 Clinical Trial.
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.
Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Gaillard ML, Meems L; ONYX study group. Eriksson BI, et al. J Thromb Haemost. 2007 Aug;5(8):1660-5. doi: 10.1111/j.1538-7836.2007.02644.x. J Thromb Haemost. 2007. PMID: 17663737 Clinical Trial.
170 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page